The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.
 
Arielle G. Bensimon
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
Yichen Zhong
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Umang Swami
No Relationships to Disclose
 
Allison Briggs
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
Joshua Young
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
Yuan Feng
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
Yan Song
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
James Signorovitch
Consulting or Advisory Role - Merck Sharp & Dohme (Inst)
Research Funding - Merck Sharp & Dohme (Inst)
 
Oluwakayode Adejoro
Employment - Eisai; Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Abhiroop Chakravarty
Employment - Complete Health Economics Solution (CHEORS)
 
Mei Chen
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Rodolfo F. Perini
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)